Mode
Text Size
Log in / Sign up
N/A N=27 Randomized Basic Science

How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?

Non-alcoholic Fatty Liver Disease (NAFLD)

Enrolled (actual)
27
Serious AEs
0.0%
Results posted
May 2021
Primary outcome: Primary: Production Rate of VLDL-1 Triacylglycerol (TAG) — 20.9; 18.9; 16.6; 12.4 grams/day — p=<0.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
High sugar low starch diet (Other); Low sugar high starch diet (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
Male
Sponsor
Bruce A. Griffin
Primary completion
Aug 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Production Rate of VLDL-1 Triacylglycerol (TAG)
20.9; 18.9; 16.6; 12.4 <0.05 sig
PRIMARY
Production Rate VLDL-1 Apoprotein B
481; 492; 546; 414 <0.05 sig
SECONDARY
Kinetics of Systemic Non-esterified Fatty Acids by [C-13]-Trace-labelled Palmitate
169; 147; 168; 168 <0.05 sig
SECONDARY
De Novo Lipogenesis (Rate of Triacylglycerol (TAG) Synthesis in the Liver) as Measured by Contribution to VLDL-1 TAG Production Rate
1.66; 1.59; 1.32; 0.56 <0.05 sig
SECONDARY
Intra-hepatocellular Lipid (IHCL) or % Liver Fat
24.2; 14.2; 3.6; 1.5 >0.05
SECONDARY
Plasma Concentration of Triacylglycerol
2.05; 1.77; 1.33; 1.13 <0.05 sig

Summary

The hypothesis of this study is that a diet high in sugars will increase abnormalities in blood lipids which are associated with increased cardiovascular disease risk, relative to a diet which is low in sugar. We predict that this potentially adverse effect of dietary sugars on blood lipids will be more pronounced in people with a raised level of stored fat inside their liver, as compared to people with a low level of stored fat.

Eligibility Criteria

Inclusion Criteria

  • Male gender,
  • Increased cardio-metabolic risk ('RISCK' criteria Jebb et al (2010) Am J Clin Nutr 92, 748-758).
  • Apo E3E3 genotype

Exclusion Criteria

  • Any abnormal result in blood screen (renal and liver function, haematology)
  • Diabetes
  • Smoker
  • Excessive alcohol consumption (>27units/week)
  • Medication likely to affect lipid metabolism
  • >3kg weight loss in preceding 3 months
  • Any medical condition (eg. GI tract, allergies) affecting lipid metabolism or ability to comply with dietary interventions
  • Involvement in any other study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01790984). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search